Format

Send to

Choose Destination
Cancer Discov. 2016 Oct;6(10):1106-1117. Epub 2016 Aug 12.

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Author information

1
The University of Texas MD Anderson Cancer Center, Houston, Texas.
2
University of Colorado Cancer Center, Aurora, Colorado.
3
AbbVie, Inc., Chicago, Illinois.
4
Dana-Farber Cancer Institute, Boston, Massachusetts.
5
AbbVie, Inc., Chicago, Illinois. Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
6
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
7
Dana-Farber Cancer Institute, Boston, Massachusetts. anthony_letai@dfci.harvard.edu.

Abstract

We present a phase II, single-arm study evaluating 800 mg daily venetoclax, a highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor in patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or unfit for intensive chemotherapy. Responses were evaluated following revised International Working Group (IWG) criteria. The overall response rate was 19%; an additional 19% of patients demonstrated antileukemic activity not meeting IWG criteria (partial bone marrow response and incomplete hematologic recovery). Twelve (38%) patients had isocitrate dehydrogenase 1/2 mutations, of whom 4 (33%) achieved complete response or complete response with incomplete blood count recovery. Six (19%) patients had BCL2-sensitive protein index at screening, which correlated with time on study. BH3 profiling was consistent with on-target BCL2 inhibition and identified potential resistance mechanisms. Common adverse events included nausea, diarrhea and vomiting (all grades), and febrile neutropenia and hypokalemia (grade 3/4). Venetoclax demonstrated activity and acceptable tolerability in patients with AML and adverse features.

SIGNIFICANCE:

Venetoclax monotherapy demonstrated clinical activity in patients with AML (relapsed/refractory or unfit for intensive chemotherapy) with a tolerable safety profile in this phase II study. Predictive markers of response consistent with BCL2 dependence were identified. Clinical and preclinical findings provide a compelling rationale to evaluate venetoclax combined with other agents in AML. Cancer Discov; 6(10); 1106-17. ©2016 AACRSee related commentary by Pullarkat and Newman, p. 1082This article is highlighted in the In This Issue feature, p. 1069.

PMID:
27520294
PMCID:
PMC5436271
DOI:
10.1158/2159-8290.CD-16-0313
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center